Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma. Reply
- PMID: 34260846
- DOI: 10.1056/NEJMc2107518
Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma. Reply
Comment on
-
Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma.N Engl J Med. 2021 Jul 15;385(3):287. doi: 10.1056/NEJMc2107518. N Engl J Med. 2021. PMID: 34260845 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical